Therapy Areas: Oncology
Cell BT Names Ofman to Board of Directors
12 July 2019 - - US-based immuno-therapy company Cell BT, Inc has appointed Joshua J. Ofman, M.D., MSHS to the CBI board of directors, the company said.
CBI is discovering and developing novel immuno-oncology therapies for the treatment of B-cell lymphomas, leukemias and selected solid tumors.
The company's biological targets and therapeutic candidates are based on the leading research and clinical practice of co-founders Jacek Pinski, M.D., Ph.D., Alan L. Epstein, M.D., Ph.D., and Peisheng Hu, Ph.D., of the Norris Comprehensive Cancer Center and Keck School of Medicine of the University of Southern California.
Pinski serves as CBI's chief medical officer, and Epstein as CBI's chief scientific officer.
Ofman was recently appointed chief of corporate strategy and External Affairs at Grail, Inc., a company that is developing diagnostic products for the early detection of cancer, when treatment may be more successful.
Prior to joining Grail, Ofman spent 16 years with Amgen, most recently as senior vice president, Global Value Access and Health Policy.
Before joining Amgen in 2003, Ofman was a member of the academic faculty in the Department of Medicine and Health Services Research, University of California, Los Angeles School of Medicine, Cedars-Sinai Medical Center.
He also served as senior vice president of Zynx Health Inc., a healthcare IT company, and subsidiary of the Cerner Corp.
Dr. Ofman obtained his undergraduate degree from the University of California, Berkeley and his medical degree from the University of California, Irvine, School of Medicine. He conducted his internship and residency in internal medicine and fellowship in digestive diseases at the UCLA Department of Medicine.
In addition, he completed a RAND/VA/UCLA fellowship in ambulatory care and health services research, specializing in technology assessment, and obtained his MSHS from the UCLA School of Public Health.
Ofman is widely published in health economics and technology assessment, public health programme evaluation, and health policy analysis.
CBI was established in February 2016 to discover and develop CAR T-cells, antibodies and associated immunotherapy cellular approaches for treating hematologic and solid tumors.
Based on the research and clinical practice of the company's three scientific founders at the Norris Comprehensive Cancer Center and Keck School of Medicine at the University of Southern California - Jacek Pinski, M.D., Ph.D., Alan L. Epstein, M.D., Ph.D., and Peisheng Hu, Ph.D., CBI has engineered a series of cell- and molecular-based technologies, including antigen and targeted receptors, monoclonal antibodies, and fusion proteins used in conjunction with immune system cells in order to effect a targeted immune response to various types of cancer.
Among other pipeline programs, CBI has discovered and is developing an advanced approach to CAR-T/antibody constructs utilising the company's novel next generation co-stimulatory and co-signaling domains.
CBI plans to commence clinical development of the company's lead program in certain B-cell lymphomas and leukemias in the second half of 2020.
CBI has also advanced the development of a novel immuno-prognostic bioassay that measures a critical immune suppressor cell population found in blood samples of cancer patients.
This test has potential to be used in combination with therapeutic agents in order to enable the monitoring of tumor regression, with the potential to provide a novel method to determine early tumor recurrence.